Two additional female patients also received at least one cycle of HER3-DXd but had to be replaced because medical monitoring revealed that one specific inclusion criterion had not been met at enrollment (both patients had received previous systemic treatment for LMD before enrollment) (Supplementary Table 1). Here, ERBB3 is linked to Langer mesomelic dysplasia.